IP Library Granted Patent US 7,968,533
Granted Patent B2
US 7,968,533 · App. 11/715,594 · Granted Jun 28, 2011

Ethyl nitrite as a gastrointestinal smooth muscle relaxant and diagnostic and therapeutic uses thereof

Assignee: Duke University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,533
App. No.
11/715,594
Granted
Jun 28, 2011
Kind
B2
Abstract

The present invention provides compositions comprising a gas and a gastrointestinal smooth muscle relaxing agent comprising ethyl nitrite in a therapeutically effective amount. The present invention also provides methods of relaxing gastrointestinal smooth muscle, alleviating contraction or spasm of gastrointestinal smooth muscle to facilitate a diagnostic medical procedure and treating or preventing a gastrointestinal disorder using the compositions of the invention.

Claims (20)

1. A method of relaxing gastrointestinal smooth muscle in a subject in need thereof comprising topically contacting said smooth muscle with a gaseous composition comprising a homogenous blend of nitrogen and ethyl nitrite in a therapeutically effective amount, wherein said gaseous composition comprises less than 48 ppmv ethanol, wherein the gaseous composition is delivered to the gastrointestinal tract of the subject.

2. The method of claim 1 , wherein the therapeutically effective amount ranges from 0.1 to 1000 ppm.

3. The method of claim 1 , wherein the therapeutically effective amount ranges from 0.1 to 100 ppm.

4. The method of claim 1 , wherein the therapeutically effective amount ranges from 0.1 to 10 ppm.

5. The method of claim 1 , wherein said gas comprises less than 5 ppm NO2.

6. The method of claim 1 , wherein said gas comprises less than 25 ppm NO.

7. A method of alleviating contraction or spasm of gastrointestinal smooth muscle associated with a medical procedure in a subject comprising topically contacting said smooth muscle with a gaseous composition comprising a homogenous blend of nitrogen and ethyl nitrite in a therapeutically effective amount, wherein said gas comprises less than 48 ppmv ethanol, wherein the gaseous composition is delivered to the gastrointestinal tract of the subject.

8. The method of claim 7 , wherein the therapeutically effective amount ranges from 0.1 to 1000 ppm.

9. The method of claim 7 , wherein the therapeutically effective amount ranges from 0.1 to 100 ppm.

10. The method of claim 7 , wherein the therapeutically effective amount ranges from 0.1 to 10 ppm.

11. The method of claim 7 , wherein said gas comprises less than 5 ppm NO2.

12. The method of claim 7 , wherein said gas comprises less than 25 ppm NO.

13. The method of claim 7 , wherein the medical procedure is an endoscopic procedure.

14. A method of treating a gastrointestinal disorder associated with smooth muscle constriction in a subject in need thereof comprising topically administering a therapeutically effective amount of a gaseous composition comprising a homogenous blend of nitrogen and ethyl nitrite to said subject thereby relaxing said gastrointestinal smooth muscle and treating said gastrointestinal disorder, wherein said gas comprises less than 48 ppmv ethanol, wherein the gaseous composition is delivered to the gastrointestinal tract of the subject.

15. The method of claim 14 , wherein the therapeutically effective amount ranges from 0.1 to 1000 ppm.

16. The method of claim 14 , wherein the therapeutically effective amount ranges from 0.1 to 100 ppm.

17. The method of claim 14 , wherein the therapeutically effective amount ranges from 0.1 to 10 ppm.

18. The method of claim 14 , wherein said gas comprises less than 5 ppm NO2.

19. The method of claim 14 , wherein said gas comprises less than 25 ppm NO.

20. A method of reversibly modifying duodenal motility and contractile activity of the sphincter of Oddi comprising directly contacting the sphincter of Oddi with a gaseous composition comprising a homogenous blend of nitrogen and ethyl nitrite in a therapeutically effective amount, wherein said gaseous composition comprises less than 48 ppmv ethanol, wherein the gaseous composition is delivered to the gastrointestinal tract of the subject.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2010
From: N30 PHARMACEUTICALS, LLC
To: DUKE UNIVERSITY
Reel/Frame 023797/0699 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2010
From: STAMLER, JONATHAN S.; BAILLIE, JOHN; REYNOLDS, JAMES D.
To: DUKE UNIVERSITY
Reel/Frame 023772/0915 →
CHANGE OF NAME Recorded Jun 18, 2009
From: NITROX, LLC
To: N30 PHARMACEUTICALS, LLC
Reel/Frame 022843/0448 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2009
From: HURLEY, KEVIN P.
To: NITROX, LLC
Reel/Frame 022825/0703 →
Continuity (2)
Provisional Application 60780311 · Mar 7, 2006
Related Publication 20080058425A1 · Mar 6, 2008